Polo Like Kinase 2 tumour suppressor and cancer biomarker: New perspectives on drug sensitivity/resistance in cancer

Oncotarget

Volumn 3, Issue 1, 2012, Pages 78-83

  Coley, Helen M ^a   Hatzimichael, Eleftheria ^b   Blagden, Sarah ^c   McNeish, Iain ^d   Thompson, Alastair ^e   Crook, Tim ^e   Syed, Nelofer ^f  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy resistance; Collateral sensitivity; Polo like kinases

Indexed keywords

PLK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

ANIMAL; CARCINOMA; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863215537     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.332     Document Type: Article

References (26)

1. Bahassi EM. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. ExpBiol and Medicine 2011; 236: 648-657.
2. Simmons DL, Neel BG, Stevens R, Evett G, Erikson RL. Identification of an early growth response gene encoding a novel putative protein kinase. Mol Cell Biol 1992; 12: 4164-4169.
3. Burns TF, Fei P, Scata KA, et al. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells. Mol Cell Biol 2003; 23: 5556-5571.
4. Syed N, Smith P, Sullivan A, Farrell PJ, Crawford D, Griffin B, Dyer MS, Karran L, O'Nions J, Spender L, Allday M, Crook T. Transcriptional silencing of Snk/Plk2 occurs at high frequency in B cell neoplasia. Blood 2006; 107: 250-256.
5. Hatzimichael E, Dasoula A, Benetatos L, Syed N, Dranitsaris G, Crook T and Bourantas K. Study of specific genetic and epigenetic variables in multiple myeloma. Leuk Lymphoma 2010; 51: 2270-2274.
6. Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G, Bourantas KL and Crook T. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011 Feb 22.
7. Savage P, Stebbing J, Bower M, Crook T. Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Prac Oncol 2009; 6: 43-52.
8. Glasspool RM, Teodoridis JM and Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94: 1087-92.
9. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek PW, McNeishI, Lovell DP, Blagden SP, Schmid P, Hatzimichael E, Crook T. Polo-like kinase 2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Research 2011; 71: 3317-3327.
10. Bredberg A and Bodmer W. Cytostatic drug treatment causes seeding of gene promoter methylation. Eur J Cancer 2007; 43: 947-954.
11. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumour growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009; 8: 4168-75.
12. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC and Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Rep 2009; 18: 47-56.
13. De Viron E, Knoops L, Connerotte T, Smal C, Michaux L, Saussoy P, Vannuffel P, Beert E, Vekemans M-C, Hermans C, Bontemps F and Van Den Neste E. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response. Br J Haematol 2009; 147: 641-652.
14. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11: 498-512.
15. Coley HM, Mohammed Safuwan Nur Arnida, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, Madhuri K, Lovell DP and Crook T. The Cyclin-Dependent Kinase Inhibitor p57Kip2 is epigenetically regulated in carboplatin-resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. Br J cancer 2011 (IN PRESS)
16. Hall MD, Handley MD, Gottesman MM. Is resistance usefless? Multidrug resistance and collateral sensitivity. Trends in Pharmacological Sciences 2009; 30: 546-56.
17. Tew KD and Wang AL. Selective cytotoxicity of haloethylnitrosoureas in a carcinoma cell line resistant to bifunctional nitrogen mustards. Mol Pharmacol 1982; 21:729-738.
18. Dean SW, Gibson NW and Tew KD. Selection of nitrogen mustard resistance in a rat tumor cell line results in loss of guanine-O6-alkyl transferase activity. Mol Pharmacol 1986; 30:77-80.
19. Nakajima K, Isonishi S, Saito M, Tachibana T, Ishikawa H. Characterisation of two independent, exposure - time dependent paclitaxel -resistant human ovarian carcinoma cell lines. Hum Cell 2010; 23: 156-63.
20. Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ, Choi CH. Concnetration-dependent collateral sensitivity of cispltin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 2005; 328: 618-22.
21. Marverti G, Ligabue A, Paglietti G, Corona P, Piras S, Vitale G, Guerrieri D, Luciani R, Costi MP, Frassineti C, Moruzzi MS. Collateral sensitivity to novel thymidylate synethase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. Eur J Pharmacol 2009; 615: 17-26..
22. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV. Kinase addiction and bi-phasic sensitivity-resistance of BCR-Abl-and Raf1 expressing cells to imatinib and geldanamycin. Cancer Biology and Therapy 2005; 4: 484-90.
23. Chappell WH, Steelman LS, Long JM and 23 others. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-64.
24. McCubrey JA, Steelman LS, Abrams SL et al. Targeting survival cascades induced by activation of raf/ras/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukaemia therapy. Leukemia 2008; 22: 708-22.
25. Chen X, Stoeck A, Lee Sj, Shihl M, Wang MM, Wang T-L. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signalling pathways in ovarian cancer. Oncotarget 2010; 1: 210-18.
26. Ando K, Ohmori T, Inoue F and 11 others. Enhancement of sensitivity to tumour necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 2005; 11: 8872-9.